• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Acrivon Therapeutics Inc.

    3/28/25 9:08:31 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRV alert in real time by email
    S-8 1 d945264ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 28, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ACRIVON THERAPEUTICS, INC.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   82-5125532
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
      Identification No.)

    480 Arsenal Way, Suite 100

    Watertown, Massachusetts 02472

    (Address of principal executive offices) (Zip code)

    Acrivon Therapeutics, Inc. 2022 Equity Incentive Plan

    Acrivon Therapeutics, Inc. 2022 Employee Stock Purchase Plan

    (Full title of the plans)

    Peter Blume-Jensen, M.D., Ph.D.

    Chief Executive Officer

    Acrivon Therapeutics, Inc.

    480 Arsenal Way, Suite 100

    Watertown, Massachusetts 02472

    (Name and address of agent for service)

    (617) 207-8979

    (Telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    Acrivon Therapeutics, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering (a) 1,561,563 shares of the Registrant’s Common Stock, par value $0.001 per share (the “Common Stock”) issuable to eligible persons under the Acrivon Therapeutics, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), which Common Stock is in addition to the shares of Common Stock registered on the Registrant’s Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on November 17, 2022 (File No. 333-268426), March 29, 2023 (File No. 333-270923) and March 29, 2024 (File No. 333-278365) and (b) 312,312 shares of Common Stock issuable to eligible persons under the Acrivon Therapeutics, Inc. 2022 Employee Stock Purchase Plan (the “2022 ESPP”), which Common Stock is in addition to the shares of Common Stock registered on the Registrant’s Form S-8 filed with the Commission on November 17, 2022 (File No. 333-268426), March 29, 2023 (File No. 333-270923) and March 29, 2024 (File No. 333-278365) (collectively, the “Prior Registration Statements”).

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the 2022 Plan and the 2022 ESPP, are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”).

    PART II

     

    ITEM 3.

    INCORPORATION OF DOCUMENTS BY REFERENCE

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

     

      (a)

    The Registrant’s Annual Report on Form 10-K for the year December 31, 2024, filed with the Commission on March 27, 2025 (the “2024 Annual Report”);

     

      (b)

    The Registrant’s Current Reports on Form 8-K, filed with the Commission on March  14, 2025 and March 25, 2025; and

     

      (c)

    The description of the Common Stock contained in the Registrant’s Registration Statement on Form 8-A, filed with the Commission on November 7, 2022 (File No. 001-41551) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.1 to the 2024 Annual Report.

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.


    For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    ITEM 8.

    EXHIBITS

     

    Exhibit
    Number
      

    Description

      4.1    Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-41551) filed with the Securities and Exchange Commission on November 17, 2022).
      4.2    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K (File No. 001-41551) filed with the Securities and Exchange Commission on November 17, 2022).
      4.3    2022 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Notice of Exercise, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Registration Statement on Form S-1/A (File No. 333-267911), filed with the Securities and Exchange Commission on November 3, 2022).
      4.4    2022 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Company’s Registration Statement on Form S-1/A (File No. 333-267911), filed with the Securities and Exchange Commission on November 3, 2022).
      5.1*    Opinion of Sidley Austin LLP.
     23.1*    Consent of Sidley Austin LLP (included in Exhibit 5.1).
     23.2*    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.
     24.1*    Power of Attorney (included on the signature page of this Form S-8).
    107*    Calculation of Filing Fee Table.

     

    *

    Filed herewith


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts, on this 28th day of March, 2025.

     

    Acrivon Therapeutics, Inc.
    By:  

    /s/ Peter Blume-Jensen

        Peter Blume-Jensen, M.D., Ph.D.
      Chief Executive Officer and President

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Peter Blume-Jensen and Rasmus Holm-Jorgensen, and each of them, as his or her true and lawful agents, proxies and attorneys-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this Registration Statement together with all schedules and exhibits thereto and any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (iii) act on and file any supplement to any prospectus included in this Registration Statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and (iv) take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his substitutes may lawfully do or cause to be done by virtue thereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Peter Blume-Jensen

    Peter Blume-Jensen, M.D., Ph.D.

      

    Chief Executive Officer, President and Chairman of the Board

    (Principal Executive Officer)

      March 28, 2025

    /s/ Rasmus Holm-Jorgensen

    Rasmus Holm-Jorgensen

      

    Chief Financial Officer

    (Principal Financial Officer)

      March 28, 2025

    /s/ Katharine Peterson

    Katharine Peterson

      

    Chief Accounting Officer

    (Principal Accounting Officer)

      March 28, 2025

    /s/ Charles Baum

    Charles Baum, M.D., Ph.D.

       Director   March 28, 2025

    /s/ Kristina Masson

    Kristina Masson, Ph.D., M.B.A.

       Executive Vice President, Business Operations, Director   March 28, 2025

    /s/ Ivana Magovcevic-Liebisch

    Ivana Magovcevic-Liebisch, Ph.D., J.D.

       Director   March 28, 2025


    /s/ Derek DiRocco

    Derek DiRocco, Ph.D.

       Director   March 28, 2025

    /s/ Santhosh Palani

       Director   March 28, 2025
    Santhosh Palani, Ph.D., CFA     

    /s/ Sharon Shacham

       Director   March 28, 2025
    Sharon Shacham, Ph.D., M.B.A.     

    /s/ Michael Tomsicek

       Director   March 28, 2025
    Michael Tomsicek, M.B.A.     
    Get the next $ACRV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACRV

    DatePrice TargetRatingAnalyst
    5/5/2025$6.00Overweight
    Piper Sandler
    1/31/2025Overweight
    KeyBanc Capital Markets
    9/16/2024$16.00Neutral → Buy
    Ladenburg Thalmann
    4/29/2024Buy → Neutral
    Ladenburg Thalmann
    3/1/2024$14.00Mkt Outperform
    JMP Securities
    12/15/2023$17.00 → $12.00Buy
    Jefferies
    10/5/2023Buy
    Maxim Group
    6/2/2023$25.00Outperform
    Oppenheimer
    More analyst ratings

    $ACRV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Perceptive Advisors Llc bought $20,000,500 worth of shares (2,353,000 units at $8.50) (SEC Form 4)

      4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

      4/15/24 8:53:49 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Acrivon Therapeutics with a new price target

      Piper Sandler resumed coverage of Acrivon Therapeutics with a rating of Overweight and set a new price target of $6.00

      5/5/25 8:30:14 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KeyBanc Capital Markets initiated coverage on Acrivon Therapeutics

      KeyBanc Capital Markets initiated coverage of Acrivon Therapeutics with a rating of Overweight

      1/31/25 8:29:16 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acrivon Therapeutics upgraded by Ladenburg Thalmann with a new price target

      Ladenburg Thalmann upgraded Acrivon Therapeutics from Neutral to Buy and set a new price target of $16.00

      9/16/24 7:17:32 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRV
    Leadership Updates

    Live Leadership Updates

    See more
    • Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

      Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the ongoing ACR-2316 Phase 1 study in selected solid tumor types WATERTOWN, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acriv

      4/7/25 4:05:00 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

      WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided business highlights. "On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year

      3/28/24 8:00:00 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

      WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors. "Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precisi

      3/4/24 8:00:00 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

      Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR) >5.6 months (not yet reached) observed in OncoSignature-positive (BM+) patients, a majority of whom were refractory to last prior therapy, and cORR of 50% and mDOR >10 months (not yet reached) for BM+ patients who had relapsed on last prior therapy Three dose escalation cohorts completed in ACR-2316 Phase 1 trial with tumor shrinkage observed already at dose level (DL)3, below projected recommended Phase 2 dose AACR presentation of ACR-2316 revealing mec

      5/14/25 4:10:00 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

      Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tumor cell death, and the mechanisms underlying its superior potency observed preclinically Phase 1 trial of ACR-2316 ahead of schedule with three dose-escalation cohorts completed; solid tumor shrinkage already observed at dose level three, well below the projected recommended Phase 2 dose WATERTOWN, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and dev

      4/25/25 8:00:00 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

      Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the ongoing ACR-2316 Phase 1 study in selected solid tumor types WATERTOWN, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acriv

      4/7/25 4:05:00 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Acrivon Therapeutics Inc.

      SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

      7/10/24 8:34:52 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Acrivon Therapeutics Inc.

      SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

      7/10/24 8:29:53 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Acrivon Therapeutics Inc. (Amendment)

      SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

      4/15/24 8:21:55 AM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRV
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Acrivon Therapeutics Inc.

      SCHEDULE 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

      5/15/25 5:24:39 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Acrivon Therapeutics Inc.

      S-8 - Acrivon Therapeutics, Inc. (0001781174) (Filer)

      5/14/25 4:47:13 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Acrivon Therapeutics Inc.

      10-Q - Acrivon Therapeutics, Inc. (0001781174) (Filer)

      5/14/25 4:16:08 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Blume-Jensen Peter covered exercise/tax liability with 19,904 shares (SEC Form 4)

      4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

      5/23/25 4:58:19 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Accounting Officer Peterson Katharine covered exercise/tax liability with 99 shares, decreasing direct ownership by 2% to 4,320 units (SEC Form 4)

      4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

      5/16/25 4:21:13 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Miller Mary covered exercise/tax liability with 184 shares, decreasing direct ownership by 0.50% to 36,323 units (SEC Form 4)

      4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

      5/16/25 4:20:06 PM ET
      $ACRV
      Biotechnology: Pharmaceutical Preparations
      Health Care